# Safety and Efficacy Study of Ladostigil in Mild to Moderate Probable Alzheimer's Disease

> **NCT01354691** · PHASE2 · COMPLETED · sponsor: **Avraham Pharmaceuticals Ltd** · enrollment: 200 (actual)

## Conditions studied

- Alzheimer's Disease
- Dementia
- Memory Loss
- Cognitive Impairment

## Interventions

- **DRUG:** ladostigil hemitartrate

## Key facts

- **NCT ID:** NCT01354691
- **Lead sponsor:** Avraham Pharmaceuticals Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-02
- **Primary completion:** 2012-09
- **Final completion:** 2013-03
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2020-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01354691

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01354691, "Safety and Efficacy Study of Ladostigil in Mild to Moderate Probable Alzheimer's Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01354691. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*